Gordon G Pugh Net Worth

The estimated Net Worth of Gordon G Pugh is at least $1.78 Milion dollars as of 12 December 2016. Gordon Pugh owns over 21,458 units of Alkermes plc stock worth over $673,682 and over the last 13 years Gordon sold ALKS stock worth over $1,108,351.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Gordon Pugh ALKS stock SEC Form 4 insiders trading

Gordon has made over 57 trades of the Alkermes plc stock since 2011, according to the Form 4 filled with the SEC. Most recently Gordon exercised 21,458 units of ALKS stock worth $355,130 on 12 December 2016.

The largest trade Gordon's ever made was exercising 75,347 units of Alkermes plc stock on 16 September 2013 worth over $1,157,330. On average, Gordon trades about 13,879 units every 29 days since 2011. As of 12 December 2016 Gordon still owns at least 25,355 units of Alkermes plc stock.

You can see the complete history of Gordon Pugh stock trades at the bottom of the page.

What's Gordon Pugh's mailing address?

Gordon's mailing address filed with the SEC is 850;852, Winter Street, Lincoln, Middlesex County, Massachusetts, 02451, United States.

Insiders trading at Alkermes plc

Over the last 13 years, insiders at Alkermes plc have traded over $407,046,771 worth of Alkermes plc stock and bought 86,119 units worth $2,034,840 . The most active insiders traders include Corp Plc Elan Science Three..., Richard F Pops a James M Frates. On average, Alkermes plc executives and independent directors trade stock every 5 days with the average trade being worth of $1,083,232. The most recent stock trade was executed by David Joseph Gaffin on 3 August 2024, trading 2,014 units of ALKS stock currently worth $53,512.

What does Alkermes plc do?

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.

Complete history of Gordon Pugh stock trades at Alkermes plc

Alkermes plc executives and stock owners

Alkermes plc executives and other stock owners filed with the SEC include:

• Richard Pops,
  Chairman of the Board, Chief Executive Officer
• Craig Hopkinson,
  Executive Vice President, Research and Development and Chief Medical Officer
• David Gaffin,
  Senior Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
• James Frates,
  Chief Financial Officer, Senior Vice President
• Michael Landine,
  Senior Vice President - Corporate Development, Chief Risk Officer
• Richard F. Pops,
  Chairman & CEO
• Dr. Craig C. Hopkinson,
  Exec. VP of R&D and Chief Medical Officer
• David Joseph Gaffin,
  Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec.
• Frank Wilson,
  Independent Director
• Richard Gaynor,
  Independent Director
• Michael J. Landine,
  Sr. VP of Corp. Devel. & Chief Risk Officer
• Paul Mitchell,
  Independent Director
• Robert Breyer,
  Independent Director
• David Anstice,
  Lead Independent Director
• Nancy Snyderman,
  Independent Director
• Wendy Dixon,
  Independent Director
• Nancy Wysenski,
  Independent Director
• Shane Cooke,
  Director
• Iain Brown,
  Senior Vice President - Finance, Chief Accounting Officer
• Peter Norman,
  Sr. VP of Policy & Gov. Relations
• Iain Michael Brown,
  Sr. VP & CFO
• Dr. Floyd E. Bloom M.D.,
  Founder
• Stephen Schiavo,
  Sr. VP of HR
• Eva Stroynowski,
  VP of Product & R&D Communications, Public Affairs
• Sandra Coombs,
  Co-Head of Investor Relations
• Blair C. Jackson,
  Exec. VP & COO
• Dr. Floyd E. Bloom,
  Founder
• Floyd E Bloom,
  Director
• Elliot Ehrich,
  SVP, R&D & CMO, Alkermes, Inc.
• Mark Stejbach,
  Chief Commercial Officer
• James A. Jr. Robinson,
  President & COO,Alkermes, Inc.
• Nancy Lurker,
  Director
• Rebecca Peterson,
  SVP, Corporate Communications
• Geraldine Henwood,
  Director
• Kathryn L Biberstein,
  SVP, GC, Secretary, Alks, Inc.
• Gordon G Pugh,
  SVP, COO & CRO, Alkermes, Inc.
• James L Botkin,
  SVP, Alkermes Gainesville LLC
• Mark B Skaletsky,
  Director
• Corp Plc Elan Science Three...,
  
• Christian Todd Nichols,
  SVP, Chief Commercial Officer
• Brian P Mckeon,
  Director
• David Angelo Jr. Daglio,
  Director
• Blair Curtis Jackson,
  EVP, Chief Operating Officer
• Emily Peterson Alva,
  Director
• Cato T Laurencin,
  Director
• Christopher I Wright,
  Director
• Samuel Joseph Parisi,
  VP, Finance (Interim PAO)